Personal Precise Treatment on Psoriasis and Psoriatic Arthritis

Dermatologic Disease Clinical Trial

Official title:

Personal Precise Treatment on Psoriasis and Psoriatic Arthritis and Investigate the Mechanisms of Biological Agents Induced Systemic Lupus Erythematosus

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04915105
• Other study ID #: CE20043B
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 31, 2021
• Est. completion date: May 31, 2025

Study information

• Verified date: May 2021
• Source: Taichung Veterans General Hospital
• Contact: Chung-Yang Yen, MDPhD
• Phone: 886423592525
• Email: vernayen[@]yahoo.com.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Part of psoriasis and psoriatic arthritis patients treated with biologics and met primary failure. Therefore, we are going to create a cell based platform to evaluate the treatment effects of different biologics on psoriasis and psoriatic arthritis patients before prescribed by physicians

Description:

PBMCs isolated from psoriasis and psoriatic arthritis and incubated with Group A streptococcus and different biologics for 24 hours. Cytokines expression in the culture supernatants will be measured and the data can be reference for physician's prescription.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• 1. Healthy control without underline disease such as psoriasis and psoriatic arthritis. 2. Psoriasis been diagnosed for over six months and PASI >10. 3.Psoriatic arthritis been diagnosed for over six months and >1 swallow and tender joints

Exclusion Criteria:

• nil

Related Conditions & MeSH terms

• Arthritis, Psoriatic
• Dermatologic Disease
• Psoriasis
• Skin Diseases

Intervention

Diagnostic Test:
• Markers data from PBMCs
Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PASI score	Psoriasis skin condition and severity	2 weeks to 3 months
Primary	swelling joint count and tenderness joint count	PSA severity	2 weeks to 3 months
Secondary	CRP	blood test	3-6 months
Secondary	DLQI	paper to investigate patient life quality	6 months